What is new in the 2021 ESC HF guidelines regarding patients with EF>40%? - PACE-CME

What is new in the ESC HF guidelines regarding patients with EF

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Switching to a salt substitute reduces risk of stroke, CV events and death
Switching to a salt substitute reduces risk of stroke, CV events and death
ESC 2021
Switching to a salt substitute reduces risk of stroke, CV events and death
- Prof. Bruce Neal, MD, PhD
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
ESC 2021
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
- Prof Bertram Pitt
Moving the field of medicine and science is a collective exercise
Moving the field of medicine and science is a collective exercise
ESC 2021
Moving the field of medicine and science is a collective exercise
- Prof. Stephan Achenbach, MD
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
ESC 2021
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
- Prof. Stefan Anker, MD, PhD